Ken Fisher Explains How President Biden’s Policies Can Influence Healthcare Stocks

In recent years, the prospect of major drug pricing reform in the US has weighed on pharmaceutical and Healthcare stocks. According to Fisher Investments’ founder, Executive Chairman and Co-Chief Investment Officer Ken Fisher, these investor concerns are likely overblown because the government doesn’t have the ability to set broad drug prices for everyone across the US without congressional approval.